arrow
R

Ryo Nishikawa

japanese pediatric molecular neuro-oncology group (jpmng) , osaka, japan
H指数:61
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PTHP-07. Clinical and Molecular Characteristics of Japanese Medulloblastoma, SHH-Activated

PTHP-07. 日本人SHH激活型髓母细胞瘤的临床与分子特征

2025-11-110
OA
Structural and dynamic insights into the biased signaling mechanism of the human kappa opioid receptor

人类κ阿片受体偏倚信号机制的结构与动态研究

2025-10-280
OAAI
RETRACTION: Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans

撤稿:Dock180Y1811通过Src依赖性磷酸化激活Rac1,介导了PDGFRα刺激的小鼠和人类胶质瘤肿瘤发生。

2025-09-161
OA
CLINICAL CHARACTERISTICS AND MOLECULAR CHARACTERISTICS OF 244 MEDULLOBLASTOMAS IN JAPAN
2024-11-110
PRE
VOXEL-WISE, MULTIVARIABLE, COX PROPORTIONAL HAZARD STATISTICAL PARAMETER MAPPING TO INVESTIGATE THE INTERPLAY BETWEEN TUMOR LOCATION, PROGNOSTIC VARIABLES, AND EXPERIMENTAL TREATMENT IN A PHASE 3 TRIAL OF NEWLY-DIAGNOSED GLIOBLASTOMA TREATED WITH CHEMORADIATION WITH OR WITHOUT BEVACIZUMAB
2024-11-110
PRE
Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study
2024-11-020
PRE
CLINICAL AND MOLECULAR CHARACTERISTICS OF JAPANESE MEDULLOBLASTOMA, WNT-ACTIVATED
2024-06-180
OAAI
LONG-TERM OUTCOMES AND COMPLICATION MANAGEMENT IN CNS GERM CELL TUMORS: INSIGHTS FROM A PHASE II HISTOPATHOLOGY-STRATIFIED TREATMENT TRIAL
2024-06-180
OAAI
Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study

3/4组髓母细胞瘤的亚型作为减少颅脊髓照射剂量的患者的潜在预后生物标志物: 日本儿科分子神经肿瘤学小组研究

2023-09-250
OAAI